Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Morbidity through 3 Years of Age in Children of Women Using Methamphetamine during Pregnancy: A National Registry Study

R. Gabrhelík, S. Skurtveit, B. Nechanská, V. Mravčík, M. Handal

. 2023 ; 29 (1) : 19-29. [pub] 20221124

Language English Country Switzerland

Document type Journal Article

BACKGROUND: There is a lack of studies on methamphetamine (MA) exposure and morbidity in children beyond the perinatal period. OBJECTIVES: We compared morbidity in children (0-3 years) with prenatal MA exposure to opioid-exposed and to non-exposed children. METHODS: We used data from a Czech nationwide, registry-based cohort study (2000-2014). Children, who reached 3 years of age, of mothers hospitalized with (i) MA use disorder during pregnancy (MA; n = 194), (ii) opioid use disorder during pregnancy (opioids; n = 166), and (iii) general population (GP; n = 1,294,349) with no recorded history of substance use disorder (SUD). Information on inpatient contacts, length of stay, and diagnoses (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10]) were assessed. Crude and adjusted odds ratios (aOR), 95% confidence interval (CI) for the risk of hospitalization, and for getting diagnosis from the ICD-10 diagnosis chapters were calculated using binary logistic regression. A stratified analysis on hospitalizations with SUD of mothers was performed. RESULTS: No significant differences were found in the measures of hospitalization between the MA and opioid groups. Children prenatally exposed to MA and opioids had higher numbers of hospitalizations and diagnoses and longer stays in hospital than children in the GP. Increased risks of certain infectious and parasitic diseases were found in both MA (aOR = 1.6; CI: 1.1-2.3) and opioid (aOR = 1.9; 1.3-2.8) groups as compared to the GP group. The most pronounced difference in stratified analysis on maternal hospitalizations related to SUD after birth was observed for injury, poisoning, and certain other consequences of external causes in the strata of the MA group who had hospitalized mothers (aOR 6.3, 1.6-24.6) compared to the strata without maternal hospitalizations (aOR 1.4, 0.9-2.3). CONCLUSION: This study suggests that children born to mothers using MA during pregnancy have similar morbidity during the first 3 years of life but higher than the GP. The excess of risk was primarily due to infections and injuries in the MA group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004753
003      
CZ-PrNML
005      
20230425171713.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000527238 $2 doi
035    __
$a (PubMed)36423599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gabrhelík, Roman $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia $u Department of Addictology, General University Hospital in Prague, Prague, Czechia
245    10
$a Morbidity through 3 Years of Age in Children of Women Using Methamphetamine during Pregnancy: A National Registry Study / $c R. Gabrhelík, S. Skurtveit, B. Nechanská, V. Mravčík, M. Handal
520    9_
$a BACKGROUND: There is a lack of studies on methamphetamine (MA) exposure and morbidity in children beyond the perinatal period. OBJECTIVES: We compared morbidity in children (0-3 years) with prenatal MA exposure to opioid-exposed and to non-exposed children. METHODS: We used data from a Czech nationwide, registry-based cohort study (2000-2014). Children, who reached 3 years of age, of mothers hospitalized with (i) MA use disorder during pregnancy (MA; n = 194), (ii) opioid use disorder during pregnancy (opioids; n = 166), and (iii) general population (GP; n = 1,294,349) with no recorded history of substance use disorder (SUD). Information on inpatient contacts, length of stay, and diagnoses (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10]) were assessed. Crude and adjusted odds ratios (aOR), 95% confidence interval (CI) for the risk of hospitalization, and for getting diagnosis from the ICD-10 diagnosis chapters were calculated using binary logistic regression. A stratified analysis on hospitalizations with SUD of mothers was performed. RESULTS: No significant differences were found in the measures of hospitalization between the MA and opioid groups. Children prenatally exposed to MA and opioids had higher numbers of hospitalizations and diagnoses and longer stays in hospital than children in the GP. Increased risks of certain infectious and parasitic diseases were found in both MA (aOR = 1.6; CI: 1.1-2.3) and opioid (aOR = 1.9; 1.3-2.8) groups as compared to the GP group. The most pronounced difference in stratified analysis on maternal hospitalizations related to SUD after birth was observed for injury, poisoning, and certain other consequences of external causes in the strata of the MA group who had hospitalized mothers (aOR 6.3, 1.6-24.6) compared to the strata without maternal hospitalizations (aOR 1.4, 0.9-2.3). CONCLUSION: This study suggests that children born to mothers using MA during pregnancy have similar morbidity during the first 3 years of life but higher than the GP. The excess of risk was primarily due to infections and injuries in the MA group.
650    _2
$a těhotenství $7 D011247
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dítě $7 D002648
650    12
$a methamfetamin $x škodlivé účinky $7 D008694
650    _2
$a kohortové studie $7 D015331
650    _2
$a opioidní analgetika $x terapeutické užití $7 D000701
650    12
$a zpožděný efekt prenatální expozice $x epidemiologie $7 D011297
650    _2
$a registrace $7 D012042
650    12
$a poruchy spojené s užíváním opiátů $x epidemiologie $x farmakoterapie $7 D009293
650    _2
$a morbidita $7 D009017
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skurtveit, Svetlana $u Norwegian Institute of Public Health, Oslo, Norway $u Norwegian Centre for Addiction Research at the University of Oslo, Oslo, Norway
700    1_
$a Nechanská, Blanka $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Mravčík, Viktor $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Handal, Marte $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia $u Norwegian Institute of Public Health, Oslo, Norway
773    0_
$w MED00007942 $t European addiction research $x 1421-9891 $g Roč. 29, č. 1 (2023), s. 19-29
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36423599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171710 $b ABA008
999    __
$a ok $b bmc $g 1925069 $s 1190962
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 1 $d 19-29 $e 20221124 $i 1421-9891 $m European addiction research $n Eur Addict Res $x MED00007942
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...